Anticoagulant Reversal Agents

Introduction to Reversal Agents

Anticoagulant reversal agents, such as ciraparantag and andexanet alfa, are used to reverse the effects of anticoagulant medications, including edoxaban, rivaroxaban, and apixaban, in patients with life-threatening bleeding, as recommended by the American College of Cardiology and the European Heart Journal 1, 2, 3, 4, 5, 6, 7

Ciraparantag, a synthetic molecule, can reverse edoxaban-induced prolongation of whole blood clotting time within 10 minutes of infusion, although its use is still under investigation and not yet FDA-approved 8

Andexanet alfa is a specific FDA-approved reversal agent for rivaroxaban and apixaban, administered as an 800 mg IV bolus followed by a 960 mg IV infusion over 2 hours for patients with life-threatening bleeding who have taken these medications within 7 hours or with unknown timing of last dose, as recommended by the American College of Cardiology 1, 2, 3, 4, 5
Andexanet alfa acts as a decoy by binding to factor Xa inhibitors with high affinity, lacks catalytic activity, and cannot participate in coagulation, rapidly reducing anti-factor Xa activity by approximately 92% within minutes 4, 5
The high-dose regimen for andexanet alfa consists of an 800 mg IV bolus over 15-30 minutes, followed by a 960 mg IV infusion over 2 hours for last dose <7 hours or unknown timing, and a low-dose regimen consists of a 400 mg IV bolus followed by a 480 mg IV infusion over 2 hours for last dose >7 hours before reversal 2, 3, 6, 4
Andexanet alfa reduced anti-FXa activity by 92% from baseline in rivaroxaban-treated patients, with effective hemostasis achieved in approximately 82% of patients at 12 hours, and the effect persists for the duration of the infusion but begins to diminish 4 hours after discontinuation 4, 5

Four-factor prothrombin complex concentrate (4F-PCC) can be administered at a dose of 50 U/kg, with dosing based on INR, as shown in the following table:

2, 3, 8, 4

Monitoring for rebound anticoagulation after reversal agent administration and considering restarting anticoagulation 7-14 days after confirmed hemostasis are important aspects of post-reversal management, as recommended by the European Heart Journal 3, 7, 4
The American College of Cardiology recommends assessing the severity of bleeding, with mild bleeding defined as small amounts of blood-streaked sputum, moderate bleeding as frank blood expectoration (<100 mL/24h), and massive/life-threatening bleeding as >100 mL/24h or respiratory compromise, and continuing oral anticoagulant therapy, provided there is an appropriate indication 3, 9, 7

The European Heart Journal suggests considering local hemostatic measures, fluid resuscitation, and blood product support as needed, as well as tranexamic acid (1 g IV, repeated every 6 hours if needed) and maintaining adequate diuresis to help eliminate apixaban 6
The American College of Cardiology recommends using restrictive RBC transfusion thresholds, with a hemoglobin trigger of 70 g/L and a target of 70-90 g/L for hemodynamically stable patients, and higher thresholds for patients with cardiovascular disease, with a hemoglobin trigger of 80 g/L and a target of 100 g/L 3, 9
For moderate to massive hemoptysis, immediate actions include positioning the patient with the bleeding side down, securing the airway if respiratory compromise is present, establishing IV access, and monitoring vital signs and oxygen saturation, and bronchial artery embolization is a first-line treatment for moderate to massive hemoptysis when the bleeding source is identified 3

Thrombotic events occurred in 10-18% of patients within 30 days of administration, which is thought to be related to the temporary inhibition of tissue factor pathway inhibitor (TFPI) 1, 10, 6, 5